Table 4.
Dual Stain triage of HPV-positive results when limited genotyping is provided by the screening test in STRIDES1
| Current Test Result | N | % of Total | CIN3+ Cases | CIN3+ Immediate Risk (%) | Clinical management recommendation |
|---|---|---|---|---|---|
| DS+/HPV16+ | 178 | 1.8 | 43 | 24.2 | colposcopy |
| DS−/HPV16+ | 110 | 1.1 | 2 | 1.8 | Special Situation |
| DS+/HPV18+ | 72 | 0.7 | 4 | 5.6 | colposcopy |
| DS−/HPV18+ | 84 | 0.8 | 0 | 0.0 | Special Situation |
| DS+/HR12+ | 518 | 5.1 | 41 | 7.9 | colposcopy |
| DS−/HR12+ | 919 | 9.1 | 4 | 0.5 | 1-year return |
1
Duration of follow-up in the STRIDES cohort is currently not sufficient to estimate cumulative 3-year risks and management confidence probabilities; follow-up is ongoing
Abbreviations: HPV, human papillomavirus; DS, dual stain; STRIDES, STudying Risk to Improve DisparitiES in Mississippi; HR12, positive for pooled 12 high-risk HPV types; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; yr, year; +, positive; −, negative